search
Back to results

A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -

Primary Purpose

Metabolic Syndrome, Obesity

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Daesiho-tang
Chowiseungcheng-tang
Placebo
Sponsored by
Gachon University Gil Oriental Medical Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome focused on measuring metabolic syndrome, Daesiho-tang, Taeeumjowi-tang, Korean medicine

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female aged 18 to 65 years
  • Subject must included at least one or more of the following symptoms below

    • BMI of 30 kg/㎡ or more;
    • BMI between 25 and 29.9kg/㎡ with hypertension, taking medication or SBP ≥ 140mmHg or DBP ≥ 90mmHg at the screening visit
    • BMI between 25 and 29.9kg/㎡ with non-insulin-dependent diabetes mellitus, taking medication or fasting blood glucose > 126mg/dL at the screening visit
    • BMI between 25 and 29.9kg/㎡ with hyperlipidemia, taking medication or total cholesterol ≥ 200mg/dL or Triglyceride ≥ 150mg/dL at screening visit
  • Agreed to low-calorie diet during the trial
  • Written informed consent of the trial

Exclusion Criteria:

  • Endocrine diseases associated with weight gain, such as hypothyroidism, Cushing's syndrome, etc.
  • Heart disease (heart failure, angina pectoris, myocardial infarction)
  • Cholelithiasis
  • Severe renal disability (SCr > 2.0 mg/dL)
  • Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)
  • History of narrow angle glaucoma
  • History of stroke or temporary ischemic cardioplegia
  • History of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
  • Use of medication that can affect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medications can affect on absorption, metabolism, excretion)
  • Use of CNS stimulant medication for weight loss
  • Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
  • history of weight loss surgery, such as bariatric surgery, etc.
  • Subjects who are judged to be inappropriate for the clinical study by the researchers
  • Women who were pregnant, lactating or have the chances of pregnancy who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.)
  • Use of other investigational product within last 1 month
  • 10 percent reduction in body weight over 6 months
  • Decided to quit smoking over the last 3 months or have irregular smoking habits

Sites / Locations

  • Gachon University Gil Oriental Medical Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Daesiho-tang

Jowiseungcheung-tang

Placebo

Arm Description

Dose: 6g, three times a day, each taken before or between meals for 12 weeks

Dose: 6g, three times a day, each taken before or between meals for 12 weeks

Dose: 6g, three times a day, each taken before or between meals for 12 weeks

Outcomes

Primary Outcome Measures

Changes from baseline in body weight

Secondary Outcome Measures

Changes from baseline in body fat percentage
Changes from baseline in fat mass
Changes from baseline in Waist circumference
Changes from baseline in Waist/hip ratio
Changes from baseline in Body mass index
Changes from baseline in Lipid profile
Changes from baseline in C-reactive protein (CRP)
Changes from baseline in blood glucose
Changes from baseline in abdominal visceral fat area
Korean Obesity-related Quality of Life (QoL) scale
Korean version of Eating Attitudes Test-26

Full Information

First Posted
January 5, 2016
Last Updated
April 9, 2021
Sponsor
Gachon University Gil Oriental Medical Hospital
Collaborators
Sangji University Oriental Medical Hospital, Korea, DongGuk University
search

1. Study Identification

Unique Protocol Identification Number
NCT02651454
Brief Title
A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -
Official Title
A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
December 31, 2015 (Actual)
Primary Completion Date
May 2, 2020 (Actual)
Study Completion Date
December 2, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Gachon University Gil Oriental Medical Hospital
Collaborators
Sangji University Oriental Medical Hospital, Korea, DongGuk University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The Purpose of this trial is to investigate the efficacy and safety of Daesiho-tang and Taeeumjowi-tang on Korean obese Women with metabolic syndrome Risk factors

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Obesity
Keywords
metabolic syndrome, Daesiho-tang, Taeeumjowi-tang, Korean medicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Daesiho-tang
Arm Type
Experimental
Arm Description
Dose: 6g, three times a day, each taken before or between meals for 12 weeks
Arm Title
Jowiseungcheung-tang
Arm Type
Experimental
Arm Description
Dose: 6g, three times a day, each taken before or between meals for 12 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Dose: 6g, three times a day, each taken before or between meals for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Daesiho-tang
Other Intervention Name(s)
DSHT, Elsion Granule
Intervention Description
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
Intervention Type
Drug
Intervention Name(s)
Chowiseungcheng-tang
Other Intervention Name(s)
CST
Intervention Description
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
Primary Outcome Measure Information:
Title
Changes from baseline in body weight
Time Frame
baseline, 12 weeks
Secondary Outcome Measure Information:
Title
Changes from baseline in body fat percentage
Time Frame
baseline, 4,8,12,16 weeks
Title
Changes from baseline in fat mass
Time Frame
baseline, 4,8,12,16 weeks
Title
Changes from baseline in Waist circumference
Time Frame
baseline, 4,8,12,16 weeks
Title
Changes from baseline in Waist/hip ratio
Time Frame
baseline, 4,8,12,16 weeks
Title
Changes from baseline in Body mass index
Time Frame
baseline, 4,8,12,16 weeks
Title
Changes from baseline in Lipid profile
Time Frame
Screening visit, 12 weeks
Title
Changes from baseline in C-reactive protein (CRP)
Time Frame
Screening visit, 12 weeks
Title
Changes from baseline in blood glucose
Time Frame
Screening visit, 12 weeks
Title
Changes from baseline in abdominal visceral fat area
Time Frame
baseline, 12 weeks
Title
Korean Obesity-related Quality of Life (QoL) scale
Time Frame
baseline, 12 weeks
Title
Korean version of Eating Attitudes Test-26
Time Frame
baseline, 12 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female aged 18 to 65 years Subject must included at least one or more of the following symptoms below BMI of 30 kg/㎡ or more; BMI between 25 and 29.9kg/㎡ with hypertension, taking medication or SBP ≥ 140mmHg or DBP ≥ 90mmHg at the screening visit BMI between 25 and 29.9kg/㎡ with non-insulin-dependent diabetes mellitus, taking medication or fasting blood glucose > 126mg/dL at the screening visit BMI between 25 and 29.9kg/㎡ with hyperlipidemia, taking medication or total cholesterol ≥ 200mg/dL or Triglyceride ≥ 150mg/dL at screening visit Agreed to low-calorie diet during the trial Written informed consent of the trial Exclusion Criteria: Endocrine diseases associated with weight gain, such as hypothyroidism, Cushing's syndrome, etc. Heart disease (heart failure, angina pectoris, myocardial infarction) Cholelithiasis Severe renal disability (SCr > 2.0 mg/dL) Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase) History of narrow angle glaucoma History of stroke or temporary ischemic cardioplegia History of eating disorder such as anorexia nervosa or bulimia nervosa, etc. Use of medication that can affect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medications can affect on absorption, metabolism, excretion) Use of CNS stimulant medication for weight loss Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse) history of weight loss surgery, such as bariatric surgery, etc. Subjects who are judged to be inappropriate for the clinical study by the researchers Women who were pregnant, lactating or have the chances of pregnancy who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.) Use of other investigational product within last 1 month 10 percent reduction in body weight over 6 months Decided to quit smoking over the last 3 months or have irregular smoking habits
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yun-Kyung Song, KMD
Organizational Affiliation
Gachon University Gil Oriental Medical Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gachon University Gil Oriental Medical Hospital
City
Incheon
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
32000419
Citation
Kim HJ, Ko Y, Kim H, Cha YY, Jang BH, Song YK, Ko SG. A pilot study exploring the efficacy and safety of herbal medicine on Korean obese women with metabolic syndrome risk factors: Double blinded, randomized, multicenter, placebo controlled study protocol clinical trial. Medicine (Baltimore). 2020 Jan;99(5):e18955. doi: 10.1097/MD.0000000000018955.
Results Reference
derived

Learn more about this trial

A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -

We'll reach out to this number within 24 hrs